| Literature DB >> 32269530 |
Hong Cheng1, Tian Lu1, Jingya Wang1, Yucen Xia1, Xiaoshu Chai2, Minyi Zhang1, Yutong Yao1, Na Zhou1, Sisi Zhou1, Xinyi Chen1, Weiwei Su3, Cunzhi Liu4, Wei Yi1, Yongjun Chen1, Lin Yao1.
Abstract
Hyperglycemia induces vascular endothelial dysfunction, which contributes to the development of vascular complication of diabetes. A classic prescription of traditional medicine, HuangqiGuizhiWuwu Decoction (HGWWD) has been used for the treatment of various cardiovascular and cerebrovascular diseases, which all are related with vascular pathology. The present study investigated the effect of HGWWD treatment in streptozocin (STZ)-induced vascular dysfunction in mouse models. In vivo studies were performed using wild type mice as well as arginase 1 knockout specific in endothelial cells (EC-A1-/-) of control mice, diabetes mice and diabetes mice treated with HGWWD (60 g crude drugs/kg/d) for 2 weeks. For in vitro studies, aortic tissues were treated with mice serum containing HGWWD with or without adenoviral arginase 1 (Ad-A1) transduction in high glucose (HG) medium. We found that HGWWD treatment restored STZ-induced impaired mean velocity and pulsatility index of mouse left femoral arteries, aortic pulse wave velocity and vascular endothelial relaxation accompanied by elevated NO production in the aorta and plasma, as well as reduced endothelial arginase activity and aortic arginase 1 expression. The protective effect of HGWWD is reversed by an inhibitor of nitric oxide synthesis. Meanwhile, the preventive effect of serum containing HGWWD in endothelial vascular dysfunction is completely blocked by Ad-A1 transduction in HG incubated aortas. HGWWD treatment further improved endothelial vascular dysfunction in STZ induced EC-A1-/- mice. This study demonstrates that HGWWD improved STZ-induced vascular dysfunction through arginase 1 - NO signaling, specifically targeting endothelial arginase 1.Entities:
Keywords: HuangqiGuizhiWuwu decoction; arginase 1; diabetic vascular dysfunction; endothelial-dependent vasorelaxation; nitric oxide
Year: 2020 PMID: 32269530 PMCID: PMC7109290 DOI: 10.3389/fphys.2020.00201
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566